Who to call at Pasithea Therapeutics Corp., and when
Fundz watches for the moments Pasithea Therapeutics Corp. starts buying, and tells you who to reach.
- An alert the day Pasithea Therapeutics Corp. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pasithea Therapeutics Corp., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pasithea Therapeutics Corp.. With Fundz connected, it knows.
Pasithea Therapeutics Corp.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
pasitheatherapeutics.comAI Executive Summary
AI-powered analysis of 8-K filing content
Pasithea's Board approved compensation changes for its CEO, Dr. Tiago Reis Marques, and CFO, Daniel Schneiderman, along with stock option grants at $0.715 per share and a director retainer increase. The Board framed the changes as bringing pay closer to peer levels while conserving cash given the company's current cash constraints.
Key Takeaways
CEO Dr. Tiago Reis Marques's base salary rises to $533,000 while his target bonus drops to 55% of base salary, and CFO Daniel Schneiderman's base salary rises to $391,000 with his target bonus increas
The Board granted options to purchase 493,341 shares to Dr. Marques and 317,266 shares to Mr. Schneiderman, plus 352,266 shares in aggregate to certain employees, all at an exercise price of $0.715 pe
3 more takeaways
Related Filings (1)
1 more filing from Pasithea Therapeutics Corp. in the last 90 days
Filing Overview
What This Means
Pasithea Therapeutics Corp. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.